November 18, 2021 10:50 AM EST

J&J uncorks long-term data for Crohn's disease candidate; Age-related disease biotech earns Eli Lilly's backing

Max Gelman

Senior Editor

Paul Schloesser

Associate Editor

J&J and AbbVie are competing for the same Crohn’s disease market with their respective IL-23 drugs, Tremfya and Skyrizi. On Wednesday, J&J’s Janssen unit …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J uncorks long-term data for Crohn's disease candidate; Age-related disease biotech earns Eli Lilly's backing

Max Gelman

Senior Editor

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

J&J un­corks long-term da­ta for Crohn's dis­ease can­di­date; Age-re­lat­ed dis­ease biotech earns Eli Lil­ly's back­ing

Senior Editor

Associate Editor

Sign up to read this article for free.

J&J uncorks long-term data for Crohn's disease candidate; Age-related disease biotech earns Eli Lilly's backing